Allergy Immunotherapy Market - By Treatment Type (Subcutaneous Immunotherapy, Sublingual [Tablet, Drop]), Allergy Type (Allergic Rhinitis, Asthma, Skin & Food Allergy), Distribution Channel (Hospital, Retail, Online Pharmacy)– Global Forecast, 2024 – 2032

Allergy Immunotherapy Market Size

Allergy Immunotherapy Market size was valued at USD 1.9 billion in 2023 and is set to register growth at an 8.5% CAGR between 2024 and 2032. The growth of the market is primarily driven by the increasing number of people suffering from allergies. For instance, according to the American Academy of Allergy, Asthma, & Immunology, nearly 10% to 30% of people globally suffer from allergic rhinitis. Such a high burden of allergic conditions indicates the need for precise treatment, such as allergy immunotherapy.
 

Another significant growth driver is the rising healthcare expenditure and consumer awareness regarding the availability of advanced treatments. Prescription medicine such as Odactra has been developed and approved by the U.S. FDA. Odactra is more targeted in comparison to other available medicines and can also be taken at home at the patient’s convenience, making it accessible to a broader patient population. Additionally, researchers are currently focusing on developing more advanced treatments that can target multiple allergens simultaneously, thus elevating treatment efficacy and scope for patients. Such developments in the research field will positively impact the allergy immunotherapy market over the forecast timeline.
 

Allergy immunotherapy, often referred to as desensitization or hypo-sensitization, is a medical treatment designed to alleviate the symptoms of allergic conditions by gradually increasing a patient's tolerance to specific allergens. This treatment works by exposing the patient to gradually increasing doses of the allergen, either through subcutaneous immunotherapy (SCIT) injections or sublingual tablets or drops (SLIT).
 

Allergy Immunotherapy Market Trends

• The increasing prevalence of allergic diseases is a significant driver of the market.
   
• For instance, according to the Asthma and Allergy Foundation of America (AAFA), nearly 25 million Americans suffer from asthma.
   
• Allergic conditions are disorders of the immune system in which the body reacts abnormally to harmless substances known as allergens. These conditions can affect different parts of the body and manifest in various forms, depending on the type of allergen and the individual's sensitivity.
   
• As the incidence of allergies rises globally, there is a growing demand for effective treatments to alleviate symptoms and improve patients' quality of life. This trend is fueling the expansion of the market, as these therapies offer targeted treatment that can significantly reduce disease progression.
   
• Additionally, ongoing research and development efforts to enhance the efficacy and safety of allergy immunotherapy further bolster market growth, meeting the increasing therapeutic needs of a larger patient population.
   

Allergy Immunotherapy Market Analysis

Based on treatment type, the market is bifurcated into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The sublingual immunotherapy segment is further distinguished into tablets and drops. The subcutaneous immunotherapy (SCIT) segment dominated the market in 2023 and accounted for USD 1.1 billion.
 

• Subcutaneous immunotherapy has been administered for several years. Hence, its efficacy in treating varied allergic conditions has been well studied, making the majority of healthcare providers familiar with this type of treatment.
   
• SCIT targets a wide range of allergens, including dust mites, pollens, insect venom, etc. This broad applicability makes SCIT a versatile option for patients suffering from multiple allergic conditions.
   
• Further, SCIT is said to induce a stronger immune response, making it the first line of preference in severe cases such as venom-induced anaphylaxis. According to Allergy, Asthma & Clinical Immunology, there are nearly 50 to 112 incidences of anaphylaxis per 100,000 people globally, requiring SCIT administration.
   
• Thus, the familiarity of healthcare professionals with SCIT, coupled with the strong immune response delivered by this treatment, will drive the market over the coming years.

Based on allergy type, the allergy immunotherapy market is bifurcated into allergic rhinitis, asthma, skin allergy, food allergy, and other allergies. The allergic rhinitis segment dominated the market in 2023 with a market share of 35.1%.
 

• Allergic rhinitis is an allergic condition characterized by inflammation of the nasal passages in response to allergens.
   
• The high prevalence of allergic rhinitis is the primary reason for the substantial market share of this segment. As per the National Institutes of Health, allergic rhinitis affects around 20% to 30% of people in the U.S. and Europe.
   
• Additionally, increasing awareness about allergy immunotherapies, combined with significant diagnosis rates, has driven the demand for immunotherapies for the treatment of allergies.
   

Based on distribution channel, the allergy immunotherapy market is categorized into hospital, retail, and online pharmacies. The hospital pharmacy segment is anticipated to reach USD 2.1 billion by 2032.
 

• Hospital pharmacies play a vital role in managing and dispensing specialized medications, such as allergy immunotherapy, which are essential for treating various allergic conditions.
   
• Additionally, hospitals often serve as primary sites for clinical trials and new drug introductions, facilitating the rapid adoption and utilization of these treatments.
   
• Further, hospital pharmacies work closely with allergists and immunologists to ensure that patients receive the appropriate formulation and dosage of their immunotherapy treatments. This coordination is essential for managing complex cases, including multiple allergies or severe allergic reactions.

North America dominated the global allergy immunotherapy market in 2023 with a revenue of USD 780.5 million and is anticipated to reach USD 1.6 billion by 2032.
 

• The region's dominance is attributed to the high prevalence of allergy conditions. According to The Asthma and Allergy Foundation of America  (AAFA), over 100 million people in the U.S. suffer from different types of allergies each year.
   
• Additionally, North America's well-developed healthcare system with high accessibility to specialized care and favorable regulatory pathways facilitates rapid market entry and adoption of new treatments.
   
• The region's high patient awareness and favorable reimbursement policies further contribute to its leading position in the market.
   

The U.S. allergy immunotherapy market was valued at USD 718.9 million in 2023.
 

• The country’s well-developed healthcare infrastructure, high prevalence of allergies, and strong emphasis on research and development contribute to its leading position.
   
• Additionally, the robust healthcare reimbursement system in the U.S. facilitates access to these treatments, further boosting their adoption.
   
• The combination of these elements ensures that the U.S. remains a dominant player in the market, driving both market growth and advancements in treatment.
   

Germany is anticipated to witness robust growth in the global allergy immunotherapy market.
 

• The increasing prevalence of allergies has accelerated the demand for effective immunotherapies in Germany. For instance, according to the National Institutes of Health (NIH), nearly 12.3 million people in the country suffer from allergic rhinitis.
   
• Germany is one of the pioneers in advanced healthcare and pharmaceutical research. Its robust healthcare infrastructure and significant investment in medical innovation provide a strong foundation for market expansion.
   
• Additionally, allergy immunotherapy is often covered under statutory health insurance, making it more accessible and affordable to patients.
   
• The presence of leading pharmaceutical companies and research institutions further stimulates Germany's position as a significant player in the market.
   

The Asia Pacific region is anticipated to witness high growth in the allergy immunotherapy market, growing at a CAGR of 8.8% over the analysis years.
 

• Rapid modernization and elevated levels of air pollution have contributed significantly to rising allergy rates in the region. According to the Global Asthma Report 2022 by the Global Asthma Network, nearly 35 million people in India suffer from asthma, indicating a high necessity for effective treatment.
   
• Additionally, significant investment in healthcare infrastructure development to offer specialized treatments, such as allergy immunotherapy, will positively drive market growth in the region.
   
• Moreover, growing patient awareness, advancements in SLIT, and increasing healthcare expenditure will further drive the market over the projected timeframe.
   

Allergy Immunotherapy Market Share

The competitive landscape in the market is diverse and highly competitive, driven by global pharmaceutical giants as well as biotechnology firms. Major players, such as Allergy Therapeutics, dominate the market space by adopting various growth strategies such as strategic partnerships, mergers & acquisitions, and collaborations to sustain their market position. Further, these companies are currently focusing on expanding their presence in emerging markets, such as those in Asia Pacific countries.
 

Allergy Immunotherapy Market Companies

Prominent players operating in the Allergy Immunotherapy industry include:

• Adamis Pharmaceuticals Corporation
• Aimmune Therapeutics
• ALK-Abelló A/S
• Allergy Therapeutics
• ASIT Biotech
• Circassia Pharmaceuticals plc
• DESENTUM OY
• DVB Technologies SA
• HAL Allergy B.V.
• HollisterStier Allergy
• LETI Pharma
• Merck KGaA
• Mylan N.V.
• Stallergenes Greer plc
• Zhejiang Wolwo Bio-pharmaceutical Co., Ltd, Inc.
   

Allergy Immunotherapy Industry News:

• In October 2023, ALK-Abelló A/S announced successful results for its phase 3 pediatric clinical trial conducted for its sublingual allergy immunotherapy (SLIT) tablet developed to treat tree-pollen-induced allergic rhinoconjunctivitis. The approved tablet is available as ITULATEK in Canada and ITULAZAX in Europe for patients aged 18 to 65 years.
   

The allergy immunotherapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Subcutaneous immunotherapy (SCIT)
• Sublingual immunotherapy (SLIT)
  • Tablets
  • Drops

Market, By Allergy Type

• Allergic rhinitis
• Asthma
• Skin allergy
• Food allergy
• Other allergies

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa